Single Dose

Single Dose Therapeutics develops neuroplastogens

designed to address maladaptive learning, enhance psychological resilience, and support cognitive health across psychiatric and neurodegenerative conditions. Our mission is to advance these drugs through rigorous research and clinical trials, ensuring they become accessible and effective treatment options for conditions with critical unmet needs and those that currently require chronic treatment.

Pipeline

		Preclinical				Clinical
		Lead Selection		IND Enabling		Clinical
Compound	Indication	Discovery	Optimization	in vitro ADMET	in vivo GLP Tox IND	Phase 1	Phase 2	Phase 3 NDA
		Preclinical				Clinical
Compound	Indication	Lead Selection		IND Enabling IND		Phase 1	Phase 2	Phase 3 NDA
SD-A001	Stimulant Use Disorder
SD-A001 is a drug candidate in the preclinical stage of development as a pharmacotherapy for stimulant use disorder. It is being evaluated for its potential to initiate neuroadaptive processes that promote allostasis in key neural circuits involved in learning and behavioral regulation. Ongoing research suggests SD-A001 enhances neuroplasticity without inducing psychotomimetic effects.
SD-A012	Parkinson's Disease
SD-A012 is in preclinical development for Parkinson's disease.

	Preclinical		Clinical
	Lead Selection	IND Enabling IND	P1	P2	P3 NDA
SD-A001 Stimulant Use Disorder
SD-A001 is a drug candidate in the preclinical stage of development as a pharmacotherapy for stimulant use disorder. It is being evaluated for its potential to initiate neuroadaptive processes that promote allostasis in key neural circuits involved in learning and behavioral regulation. Ongoing research suggests SD-A001 enhances neuroplasticity without inducing psychotomimetic effects.
SD-A012 Parkinson's Disease
SD-A012 is in preclinical development for Parkinson's disease.

News

Accelerator March 2026

Accepted into California Life Sciences FAST Program

Single Dose Therapeutics was selected as one of twelve winners for the California Life Sciences FAST California program, an advisory program pairing life sciences founders with domain experts over twelve weeks to develop commercialization strategy and prepare for investor pitches.

NIDA Drug Repurposing Challenge Winner

Single Dose Therapeutics was selected as one of four winners of the NIDA "Drug Repurposing and Repositioning Insights for Treating SUDs" Challenge for their submission "Repurposing SD-A001 for use in the Treatment of Amphetamine-Type Stimulant Use Disorder".

Single Dose

Pipeline

News

Accepted into California Life Sciences FAST Program

NIDA Drug Repurposing Challenge Winner

Contact